Inactive Instrument

Immunodiagnostic Systems Holdings PLC Stock price

Equities

IDH

GB00B01YZ052

Medical Equipment, Supplies & Distribution

Dynamic Chart
Immunodiagnostic Systems Holdings PLC's Equity Buyback announced on June 21, 2017, has expired. CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Immunodiagnostic Systems Holdings PLC from a group of investors. CI
DiaSorin S p A : Launches Antigen Test To Detect COVID-19 Infection MT
Immunodiagnostic : Agrees To $155 Million Takeover Bid From PerkinElmer MT
PerkinElmer : to Acquire UK-Based Diagnostic Company Immunodiagnostic Systems MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Immunodiagnostic Systems Holdings PLC from a group of investors for approximately £110 million. CI
Immunodiagnostic : Earnings Flash (IDH.L) IMMUNODIAGNOSTIC SYSTEMS Reports H2 Revenue GBP12.2M MT
Immunodiagnostic Systems Holdings PLC Reports Unaudited Group Revenues for the Financial Year Ended March 31, 2021 CI
Immunodiagnostic Systems Holdings PLC Provides Unaudited Revenue Guidance for the Second Half for the Fiscal Year Ended March 31, 2021 CI
Immunodiagnostic : COVID-19 Test Authorized for Emergency Use in US MT
Update: Immunodiagnostic Systems Soars 34% on Launch of COVID-19 Antigen Rapid Test Kits MT
Immunodiagnostic : Starts Selling COVID-19 Antigen Rapid Test Kits MT
Immunodiagnostic Systems Holdings PLC Announces Two SARS-CoV-2 Antigen Rapid Test Kits Are Available for Sale in the UK CI
Immunodiagnostic Systems Holdings PLC Reports Unaudited Group Financial Results for the Six Months Ended 30 September 2020 CI
Tranche Update on Immunodiagnostic Systems Holdings PLC's Equity Buyback Plan announced on June 21, 2017. CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 12-12-31
Director of Finance/CFO - 21-12-31
Members of the board TitleAgeSince
Director/Board Member - 21-06-30
Chief Executive Officer 54 12-12-31
Director of Finance/CFO - 21-12-31
More insiders
Immunodiagnostic Systems Holdings PLC is a specialist in vitro diagnostic solution provider to the clinical laboratory market. The Company develops, manufactures and markets immunoassays and automated immunoanalyser technologies. It operates through three business segments: Automated IVD, Manual IVD, and Licensing & Technology. The automated IVD business consists of 25-OH Vitamin D, specialties and instrument sales. The automated IVD business also consists of the sale or placement of its IDS-iSYS instrument, in addition to selling automated assays and consumables for use in these instruments. The Manual IVD business sells manual assays, radio immunoassays (RIA) and ELISA kits (EIA) to labs. Its assay development is focused in the clinical areas, such as calcium metabolism, bone metabolism, chronic kidney disease, hypertension, fertility and growth. Its subsidiaries include Immunodiagnostic Systems Limited, Immunodiagnostic Systems Nordic A/S and Immunodiagnostic Systems France SAS.
More about the company
  1. Stock
  2. Equities
  3. Stock Immunodiagnostic Systems Holdings PLC - London S.E.